论文部分内容阅读
礼来公司宣布abemaciclibⅢ期临床MONARCH 2试验治疗晚期或复发乳腺癌达到主终点,无病情加重,存活改善。abemaciclib是细胞周期蛋白依赖激酶(CDK)4和6抑制剂,与氟维司群(fulvestrant)伍用治疗激素受体(HR)阳性及人表皮生长因子受体2(HER2)阴性的女性患者,即内分泌治疗后病情进展的晚期或复发性乳腺癌。结果证实,与安慰剂组和单药氟维司群组比,伍用abemaciclib组无病情加重,存活明显改善。乳
Eli Lilly and Company Announces Phase III Clinical MONARCH 2 Trial of Abemaciclib to Achieve Primary Endpoints for Advanced or Recurring Breast Cancer, No Sickness, Improved Survival. Abemaciclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, a feminine patient with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative with fulvestrant, Endocrine disease progression after advanced or recurrent breast cancer. The results confirmed that, compared with the placebo group and monotherapy fulvestrant group, use of abemaciclib group no illness worsened, survival improved significantly. milk